Onkologie. 2016:10(1):26-30 | DOI: 10.36290/xon.2016.007
Present status and perspectives of immunotherapy in NSCLC
- Pneumologická klinika Thomayerovy nemocnice, Praha
Lung cancer is one of the most common cancer worldwide. There are approximately 1.8 million of new lung cancer cases, and
1.6 million deaths by lung cancer. Cure can be achieved only in initial stages of disease, but these initial stages are found in one
fifth of patiens. Majority of patiens are diagnosed with advanced disease and treated with palliative intent. The main therapeutic
modality for these patients is a systemic therapy or in combination with radiotherapy. Immunotherapy is a novel approach using
immune system itself and his ability to fight against cancer. This therapeutic approach showed a remarkable progress recently
and become a part of therapeutic recommendations.
Keywords: lung cancer, immunotherapy, PD-1, PD-L1, CTLA-4, anticancer vaccines
Published: March 1, 2016 Show citation
References
- Einhorn LH, Bond WH, Hornback N. Long-term results in combined-modality treatment of small cell carcinoma of the lung. Semin Oncol. 1978; 5(3): 309-313.
- Jansen RL, Slingerland R, Goey SH, Franks CR, Bolhuis RL, Stoter G. Interleukin-2 and inter feron-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother (1991). 1992; 12(1): 70-73.
Go to original source... - Butts Ch, Socinski MA, Mitchell PL, Thatcher N, Havel L, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncology 2014; 15(1): 59-68. Go to original source...
Go to PubMed... - Nokihara H, Katakami N, Hida T. Phase I/II study of tecemotide cancer immunotherapy for Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC). J Clin Oncol 33, 2015; (Suppl; abstr 3036). Go to original source...
- Vansteenkiste J, Byoung-Chul Ch, Vanakesa T, DePas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov O, Spiessens B, Brichard V, Debruyenne Ch, Therasse P, Altorki N. MAGRIT, a double-blind,placebo controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patiens with resected MAGE-A3-positive non-small cell lung cancer. Ann Oncol 2014: Suppl. 4. Go to original source...
- Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012; 23(Suppl 8): viii6-viii9. Go to original source...
- Vesely MD. Natural innate and adaptive imunity to cancer. Annu Rev. Immunol. 2011; 29: 235-71. Go to original source... Go to PubMed...
- Zatloukal P, Heo DS, Park K, et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care following first-line platinum-based therapy in patients with advanced non-small cell lung cancer; 2009. J Clin Oncol 27: 15s, 2009 (Suppl; abstr 8071). Go to original source...
- Reck M, Haolan Lu H, Gribkoff G, Maier S. CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology. J Clin Oncol 30, 2012 (suppl; abstr TPS7611). Go to original source...
- Brahmer J, Reckamp K, Baas P, Crin? L, Eberhardt W, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet Ch, Harbison ChT, Lestini B, Spigel D. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer May 31, 2015DOI: 10.1056/ Go to original source...
- Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crin? L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27. Go to original source...
- Garon E, Rizvi N, Hui R, et al. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer: N Engl J Med 2015; 372: 2018-2028. Go to original source...
- Herbst R, Baas P, Dong-Wan K, Felip E, at al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2015. Go to original source...